Session

Hepatobiliary and pancreatic cancer: Basic meets clinical practice

LONG-TERM SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB OR TREMELIMUMAB PLUS DURVALUMAB: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS
LONG-TERM SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB OR TREMELIMUMAB PLUS DURVALUMAB: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS

Hepatobiliary and pancreatic cancer: Basic meets clinical practice  et al.

ENDOSCOPIC ULTRASOUND (EUS): ROLE IN DETECTION AND MANAGEMENT OF PANCREATIC NEUROENDOCRINE TUMOURS (PNET) IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) PATIENTS BEYOND RADIOLOGICAL IMAGING
ENDOSCOPIC ULTRASOUND (EUS): ROLE IN DETECTION AND MANAGEMENT OF PANCREATIC NEUROENDOCRINE TUMOURS (PNET) IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) PATIENTS BEYOND RADIOLOGICAL IMAGING

Hepatobiliary and pancreatic cancer: Basic meets clinical practice  et al.

RNA N6-METHYLADENOSINE METHYLTRANSFERASE METTL3 DRIVES NAFLD-HCC AND IS A THERAPEUTIC TARGET FOR BOOSTING IMMUNOTHERAPY
RNA N6-METHYLADENOSINE METHYLTRANSFERASE METTL3 DRIVES NAFLD-HCC AND IS A THERAPEUTIC TARGET FOR BOOSTING IMMUNOTHERAPY

Hepatobiliary and pancreatic cancer: Basic meets clinical practice  et al.

IMMUNO-ONCOLOGY BIOMARKERS FOR IMPROVED DIAGNOSIS OF CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS: INSIGHTS FROM THE INFLAMMATORY AND FIBROTIC TUMOUR MICROENVIRONMENT
IMMUNO-ONCOLOGY BIOMARKERS FOR IMPROVED DIAGNOSIS OF CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS: INSIGHTS FROM THE INFLAMMATORY AND FIBROTIC TUMOUR MICROENVIRONMENT

Hepatobiliary and pancreatic cancer: Basic meets clinical practice  et al.

EFFICACY OF THE THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED PANCREATIC CANCER
EFFICACY OF THE THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED PANCREATIC CANCER

Hepatobiliary and pancreatic cancer: Basic meets clinical practice  et al.

ENDOSCOPIC ULTRASOUND (EUS): ROLE IN DETECTION AND MANAGEMENT OF PANCREATIC NEUROENDOCRINE TUMOURS (PNET) IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) PATIENTS BEYOND RADIOLOGICAL IMAGING
ENDOSCOPIC ULTRASOUND (EUS): ROLE IN DETECTION AND MANAGEMENT OF PANCREATIC NEUROENDOCRINE TUMOURS (PNET) IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) PATIENTS BEYOND RADIOLOGICAL IMAGING

RNA N6-METHYLADENOSINE METHYLTRANSFERASE METTL3 DRIVES NAFLD-HCC AND IS A THERAPEUTIC TARGET FOR BOOSTING IMMUNOTHERAPY
RNA N6-METHYLADENOSINE METHYLTRANSFERASE METTL3 DRIVES NAFLD-HCC AND IS A THERAPEUTIC TARGET FOR BOOSTING IMMUNOTHERAPY

LONG-TERM SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB OR TREMELIMUMAB PLUS DURVALUMAB: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS
LONG-TERM SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB OR TREMELIMUMAB PLUS DURVALUMAB: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS

IMMUNO-ONCOLOGY BIOMARKERS FOR IMPROVED DIAGNOSIS OF CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS: INSIGHTS FROM THE INFLAMMATORY AND FIBROTIC TUMOUR MICROENVIRONMENT
IMMUNO-ONCOLOGY BIOMARKERS FOR IMPROVED DIAGNOSIS OF CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS: INSIGHTS FROM THE INFLAMMATORY AND FIBROTIC TUMOUR MICROENVIRONMENT

EFFICACY OF THE THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED PANCREATIC CANCER
EFFICACY OF THE THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED PANCREATIC CANCER

Item 1 - 10 / 10
1